Form 4: Hookipa Pharma CEO Malte Peters Acquires Shares Through Restricted Stock Unit Grant
SEC Form 4 Filing
CEO of Hookipa Pharma, Malte Peters, reports acquisition of common stock through a restricted stock unit grant.
Summary
- On July 22, 2024, Malte Peters, the CEO of Hookipa Pharma Inc., acquired 108,695 shares of common stock.
- This acquisition was through a restricted stock unit (RSU) grant, where each RSU represents the right to receive one share of common stock.
- The RSUs will vest in two equal installments on July 22, 2025, and July 22, 2026, contingent upon Peters' continuous service through those dates.
- Following the transaction, Peters beneficially owns 108,695 shares of Hookipa Pharma Inc.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard reporting of stock grants to the CEO. The vesting schedule suggests a long-term commitment.
Positives
- The CEO's acquisition of shares may signal confidence in the company's future performance.
Future Outlook
The vesting of the RSUs is contingent upon the Reporting Person's continuous service, incentivizing continued leadership.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies as part of executive compensation packages.
Stakeholder Impact
- The transaction could have a slightly positive impact on shareholder confidence due to the CEO increasing their stake in the company.
Key Dates
| Date | Description |
|---|---|
| 07/22/2024 | Date of the transaction: Grant of restricted stock units (RSUs). |
| 07/22/2025 | First vesting date for half of the RSUs. |
| 07/22/2026 | Second vesting date for the remaining half of the RSUs. |
| 07/24/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.